Cargando…

Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review

OBJECTIVE: Discontinuation of Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, can induce symptom-relapse and even life-threatening adverse events. Due to increasing use of RUX, this so-called RUX discontinuation syndrome (RDS) is becoming more prevalent. To create better awareness for this potentially fat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houthuys, Jona F., Wilmer, Alexander P., Peetermans, Marijke, Meersseman, Philippe, Devos, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720527/ https://www.ncbi.nlm.nih.gov/pubmed/36478803 http://dx.doi.org/10.1016/j.heliyon.2022.e11782

Ejemplares similares

Impact of BMI on outcomes in respiratory ECMO: an ELSO registry study
por: Peetermans, Marijke, et al.
Publicado: (2022)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2021)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023)

Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
por: Neubauer, Andreas, et al.
Publicado: (2020)

Ruxolitinib withdrawal due to the COVID-19
por: Lucijanic, Marko, et al.
Publicado: (2021)

Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
por: Beauverd, Yan, et al.
Publicado: (2014)

Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
por: Caocci, Giovanni, et al.
Publicado: (2020)

The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
por: Neubauer, Andreas, et al.
Publicado: (2021)

Ruxolitinib and Severe COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
por: Wen, Sai, et al.
Publicado: (2022)

Response to: Ruxolitinib withdrawal due to the COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

Rickettsia typhi infection presenting as severe ARDS
por: Tran, Liem T., et al.
Publicado: (2019)

Publisher Correction: The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
por: Neubauer, Andreas, et al.
Publicado: (2021)

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
por: Passamonti, F., et al.
Publicado: (2022)

Invasive aspergillosis in a medical ICU: the spectrum of disease in 89 nonhaematology patients
por: Meersseman, W, et al.
Publicado: (2004)

Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump
por: Shamil, Eamon, et al.
Publicado: (2015)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

A Pathology-based Case Series of Influenza- and COVID-19–associated Pulmonary Aspergillosis: The Proof Is in the Tissue
por: Vanderbeke, Lore, et al.
Publicado: (2023)

Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency
por: Cassiman, David, et al.
Publicado: (2019)

Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study
por: Wauters, Joost, et al.
Publicado: (2012)

ECMO for ARDS due to COVID-19
por: Ñamendys-Silva, Silvio A.
Publicado: (2020)

SECONDARY HLH PRESENTING AS ARDS
por: Pruett, William, et al.
Publicado: (2020)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

Fixed dilated pupils in Covid-19 ARDS patients under rocuronium, reversed after discontinuation
por: Zakynthinos, George E., et al.
Publicado: (2021)

Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review
por: Hirai, Nobuyasu, et al.
Publicado: (2020)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

HYPONATREMIA SECONDARY TO VASOPRESSIN IN AN ECMO DEPENDENT PATIENT WITH SEVERE ARDS DUE TO COVID-19
por: HAFEEZ, ZEESHAN, et al.
Publicado: (2021)

Use of Almitrine and Inhaled Nitric Oxide in ARDS Due to COVID-19
por: Laghlam, Driss, et al.
Publicado: (2021)

Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation
por: Cattalini, Marco, et al.
Publicado: (2021)

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib
por: Völkel, Sara, et al.
Publicado: (2023)

PB2583: RUXOLITINIB IN SEVERE AND CRITICAL COVID19 REQUIRING CPAP
por: Festuccia, Moreno Benedetto, et al.
Publicado: (2023)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
por: Stoeva, Vera, et al.
Publicado: (2023)

Ruxolitinib in severe COVID-19 Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
por: Iastrebner, Marcelo, et al.
Publicado: (2021)

Usefulness and safety of a dedicated team to prone patients with severe ARDS due to COVID-19
por: Kimmoun, Antoine, et al.
Publicado: (2020)

NIV IN MODERATE TO SEVERE ARDS DUE TO COVID-19 PNEUMONIA: A RETROSPECTIVE COHORT STUDY
por: BOTSCH, A., et al.
Publicado: (2022)

PULSED METHYLPREDNISOLONE USAGE IN ARDS DUE TO VIRAL PNEUMONIA
por: Szeto, C.H.
Publicado: (2019)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017)

Coccidioidomycosis in Patients Treated With Ruxolitinib
por: Kusne, Yael, et al.
Publicado: (2020)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h2fb6ldcge7derjaev4huk54hm